SciBite’s platform is the culmination of decades of experience in applying semantic analytics to unstructured data. At its core are established controlled vocabularies that apply an explicit, unique meaning to scientific terms, enabling complex text to be contextualized and used as high-quality, actionable data, irrespective of its source.
This partnership will bring deeper chemistry awareness to the SciBite platform. A seamless integration of ChemAxon’s chemical recognition capabilities will enable customers to quickly and accurately extract structures from images and chemical names within scientific documents.
To extract and search a combination of chemistry and biology knowledge via a single interface and a consistent application programming interface, allows users to answer questions such as “What research has been conducted in a given disease and/or target related to a specific chemical substructure?”.
ChemAxon will also integrate SciBite’s unique semantic technology to deliver biology intelligence within its suite of applications, including ChemLocator.
“Our partnership with ChemAxon will bridge the gap between chemistry and biology and deliver unparalleled insights. ChemAxon and SciBite share a similar philosophy, providing customers with interoperable, best-of-breed solutions to further power their next-generation analytics.” said Rob Greenwood, CEO of SciBite.
“We’re conscious of the great potential in better exploitation of scientific data and are delighted to simplify evidence-based decision working with SciBite the domain expert of semantic entity recognition,” said Ferenc Csizmadia, ChemAxon CEO.
SciBite is an award-winning leading provider of semantic solutions for the life sciences industry. Headquartered in the UK, it supports its customers with offices in the UK, US and Japan. A fast, scalable solution, SciBite delivers a semantic platform across science-based industries.
ChemAxon is a leader in providing cheminformatics software for the chemistry, biotechnology, pharmaceutical and agrochemical industries. We create leading cross platform solutions, that power modern cheminformatics activities. With regional headquarters in Budapest and Cambridge, MA it supports its global customers with offices in Europe, Japan, and North America.
In this three-part blog series, we explore the challenges healthcare organizations face in unlocking patient data for real-world evidence. In part 1 Unlocking Important Real World Evidence (RWE) from Patient Data – Why and How?Read
Get in touch with us to find out how we can transform your data
© Copyright © 2023 Elsevier Ltd., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.